Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel and Pembrolizumab in Locally Advanced or Metastatic Melanoma
NCT05176470Phase 1Active, not recruiting
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lifileucel in melanoma. Primary endpoints: Feasibility of neoadjuvant administration of MK-3475 and LN-144/Lifileucel up to 2 years and Incidence of grade >= 3 treatment-emergent adverse events up to 2 years. Started Jul 2022; status: active, not recruiting.
02
Drugs
lifileucel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05176470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176470.